IN8bio (INAB) Projected to Post Earnings on Thursday

IN8bio (NASDAQ:INAB) is expected to be issuing its Q4 2025 results before the market opens on Thursday, March 12th. Analysts expect the company to announce earnings of ($0.18) per share for the quarter. Investors may review the information on the company’s upcoming Q4 2025 earning report for the latest details on the call scheduled for Friday, March 13, 2026 at 4:00 PM ET.

IN8bio Price Performance

Shares of NASDAQ:INAB opened at $1.73 on Thursday. The company’s 50 day simple moving average is $2.05 and its 200 day simple moving average is $2.00. IN8bio has a 1 year low of $1.17 and a 1 year high of $8.24. The stock has a market capitalization of $16.90 million and a price-to-earnings ratio of -0.32.

Institutional Investors Weigh In On IN8bio

Large investors have recently added to or reduced their stakes in the business. Alyeska Investment Group L.P. lifted its stake in IN8bio by 1,060.8% in the fourth quarter. Alyeska Investment Group L.P. now owns 957,484 shares of the company’s stock valued at $2,231,000 after buying an additional 875,000 shares during the period. Franklin Resources Inc. grew its position in shares of IN8bio by 381.6% during the 4th quarter. Franklin Resources Inc. now owns 914,531 shares of the company’s stock worth $2,048,000 after buying an additional 724,637 shares during the period. Two Sigma Investments LP bought a new stake in shares of IN8bio in the 3rd quarter valued at $107,000. Citadel Advisors LLC acquired a new position in shares of IN8bio during the 3rd quarter valued at $54,000. Finally, Captrust Financial Advisors bought a new position in shares of IN8bio during the 4th quarter worth about $43,000. Institutional investors and hedge funds own 92.05% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on INAB shares. Zacks Research raised shares of IN8bio to a “hold” rating in a research note on Thursday, January 15th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of IN8bio in a research report on Thursday, January 22nd. One analyst has rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $92.00.

About IN8bio

IN8bio, Inc (NASDAQ: INAB) is a clinical-stage biotechnology company focused on the development of novel immunotherapies for the treatment of cancer and neurodegenerative disorders. The company leverages insights into the body’s innate and adaptive immune systems to engineer cell-based products designed to target solid tumors, brain injuries and cognitive decline.

IN8bio’s pipeline is built on two proprietary platforms. The ENACT™ platform centers on allogeneic gamma delta T cell therapies aimed at solid tumors, with lead candidates advancing through early-stage clinical trials in glioblastoma and other oncology indications.